Particle.news
Download on the App Store
5 ARTICLES
·
5h ago

Amgen’s MariTide Delivers 20% Weight Loss in Phase 2 and Advances to 72-Week Phase 3 Trial

Amgen plans a 72-week pivotal study following phase 2 results that showed substantial weight loss alongside lower gastrointestinal side effects from a low-dose ramp-up.

An Amgen sign is seen at the company's headquarters in Thousand Oaks, California, U.S., November 6, 2019. REUTERS/Deena Beasley/File Photo
Amgen's headquarters in Thousand Oaks, Calif., in 2023.
Image
Image

Overview

  • Phase 2 data showed obese participants on monthly MariTide lost up to 20% of body weight versus about 2–3% with placebo.
  • MariTide lowered A1c by as much as 2.2 percentage points in people with type 2 diabetes and improved blood pressure and lipid measures.
  • An eight-week dose ramp-up approach reduced gastrointestinal side effects with vomiting rates falling from 90% at top dose to 22% during escalation.
  • The drug’s design combines a GLP-1 receptor agonist with a monoclonal antibody to enable once-monthly injections.
  • Amgen will initiate a 72-week Phase 3 trial in overweight and obese adults and launch additional studies later this year in cardiovascular and sleep apnea patients.